Edgemoor Investment Advisors Inc. trimmed its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 1.7% in the 4th quarter, HoldingsChannel reports. The firm owned 18,391 shares of the medical research company’s stock after selling 327 shares during the period. Edgemoor Investment Advisors Inc.’s holdings in Thermo Fisher Scientific were worth $9,568,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently bought and sold shares of TMO. Legacy Investment Solutions LLC acquired a new position in Thermo Fisher Scientific during the 3rd quarter worth $26,000. Peterson Financial Group Inc. purchased a new stake in Thermo Fisher Scientific during the 3rd quarter worth about $27,000. Barrett & Company Inc. purchased a new stake in Thermo Fisher Scientific during the 4th quarter worth about $28,000. FPC Investment Advisory Inc. purchased a new stake in Thermo Fisher Scientific during the 4th quarter worth about $28,000. Finally, Missouri Trust & Investment Co purchased a new stake in Thermo Fisher Scientific during the 4th quarter worth about $29,000. 89.23% of the stock is owned by institutional investors and hedge funds.
Insider Activity at Thermo Fisher Scientific
In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 3,775 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the transaction, the senior vice president now owns 10,816 shares of the company’s stock, valued at $5,759,736.32. This represents a 25.87 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total value of $5,166,700.00. Following the transaction, the chief executive officer now directly owns 115,174 shares in the company, valued at approximately $59,506,950.58. This represents a 7.99 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 23,900 shares of company stock valued at $13,106,062. 0.34% of the stock is owned by corporate insiders.
Analyst Ratings Changes
Thermo Fisher Scientific Stock Performance
TMO opened at $523.44 on Monday. Thermo Fisher Scientific Inc. has a 1-year low of $493.30 and a 1-year high of $627.88. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The stock’s 50 day simple moving average is $548.54 and its 200 day simple moving average is $558.79. The stock has a market cap of $197.47 billion, a P/E ratio of 31.67, a P/E/G ratio of 2.99 and a beta of 0.79.
Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last posted its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. As a group, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.
Thermo Fisher Scientific Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Friday, March 14th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, March 14th. This represents a $1.72 dividend on an annualized basis and a yield of 0.33%. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. Thermo Fisher Scientific’s dividend payout ratio is presently 10.41%.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Read More
- Five stocks we like better than Thermo Fisher Scientific
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- How to Build the Ultimate Everything ETF Portfolio
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- 3 Stocks With High ROE and Market-Beating Growth Potential
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.